6-Benzylaminopurine
CAS 1214-39-7
6-Benzylaminopurine (CAS 1214-39-7) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 14687.908333333333 nM | 11 | - |
| - | IC50 | 35981.047999999995 nM | 2 | - |
| - | AC50 | 8800.56 nM | 2 | - |
| - | EC50 | 25210 nM | 2 | - |
| - | Kd | 154500 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 6-Benzylaminopurine used for in pharmaceutical contexts?
6-Benzylaminopurine (CAS 1214-39-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 6-Benzylaminopurine?
No adverse-event association or SIDER side-effect rows are rendered for 6-Benzylaminopurine in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 6-Benzylaminopurine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Benzyladenine with EU status "restricted".
What clinical phase is 6-Benzylaminopurine in?
No phase 1-4 clinical development badge is rendered for 6-Benzylaminopurine because the matched compound identifier rows do not contain a max-phase value.